Boyu, Sinopharm among shortlisted bidders for drugmaker Mundipharma's China unit

Boyu, Sinopharm among shortlisted bidders for drugmaker Mundipharma's China unit

Photo: National Cancer Institute / Unsplash

Drugmaker Mundipharma has included Boyu Capital and state-owned Sinopharm on a shortlist of bidders for its Chinese business, two people familiar with the situation said.

Chinese buyout firms CITIC Capital and CPE are also on the shortlist for Mundipharma’s China unit, which sources have said could fetch more than $1 billion.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter